Iressa (Gefitinib) 250 mg Tablet
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Iressa 250 mg Tablet contains gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Its labelling describes it as a treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours carry activating EGFR mutations, described as blocking signals that drive cancer cell growth and spread.
Product Information
The following description reflects information associated with gefitinib and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for adults with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
- Described as blocking EGFR signalling involved in tumour growth and spread
Described Dosage & Administration
- Taken by mouth once daily, with or without food, at about the same time each day
- Swallowed whole with water; not broken, chewed or crushed
- For patients with swallowing difficulty, the labelling describes dispersing the tablet in water as directed
- Dose and duration are set by the treating doctor
Described Side Effects
Commonly described side effects include:
- Diarrhoea
- Nausea and vomiting
- Acne-like skin rash, dry skin
- Loss of appetite
- Weakness
- Sore, dry or red mouth
- Hair thinning
- Fever
- Described as possibly affecting the liver (raised liver enzymes)
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Liver function testing is described in the labelling before and during treatment
- Sudden breathlessness, cough or fever should be reported promptly (described as a risk of lung inflammation)
- New or worsening eye symptoms should be reported
- Existing lung, liver or kidney conditions should be disclosed to the doctor
- Not indicated for children or adolescents under 18 years, per manufacturer guidance
- Pregnancy or breastfeeding should be discussed with the prescriber; stored at room temperature, out of reach of children
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains gefitinib and is described for adults with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer. SDO Pharma has not independently verified these claims.
Its labelling describes one tablet by mouth once daily, swallowed whole; the manufacturer’s prescribing information covers missed doses and swallowing difficulty.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.